Innohep

Tinzaparin sodium, the active ingredient in Innohep, is a low molecular weight heparin presented as a solution for injection for subcutaneous use. It is used to prevent and treat deep vein thrombosis and pulmonary embolism in patients at risk, including those undergoing surgery.

GNH USA supplies Innohep as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Innohep, a low molecular weight heparin, acts on the venous thrombo‑embolism pathway to reduce clot formation.

Deep Vein Thrombosis: prevents clot formation and treats existing thrombi in the deep veins. Pulmonary Embolism: reduces the risk of embolic events and treats established pulmonary emboli. Post‑operative Patients: prevents venous thrombo‑embolism after surgical procedures.

Adverse reactions may occur with any anticoagulant therapy.

Common Side Effects: - Injection site pain or erythema - Minor bruising or hematoma at the injection site - Mild gastrointestinal upset - Transient headache - Nausea - Slight elevation of liver enzymes

Serious or Rare Side Effects: - Major bleeding (intracranial, gastrointestinal, or retroperitoneal) - Heparin‑induced thrombocytopenia (HIT) - Allergic or anaphylactic reactions - Spinal or epidural hematoma - Severe thrombocytopenia unrelated to HIT - Paradoxical thrombosis (e.g., skin necrosis)

Use of Innohep requires careful clinical assessment.

Assess renal function: adjust or avoid in severe renal impairment. Monitor platelet count: watch for heparin‑induced thrombocytopenia. Evaluate bleeding risk: contraindicated in active major bleeding. Use caution with concurrent anticoagulants: increased bleeding potential. Avoid in patients with known hypersensitivity to low molecular weight heparins. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Tinzaparin sodium may interact with several medicines that affect coagulation.

Major Interactions (Avoid): - Concomitant unfractionated heparin - Simultaneous warfarin during initial therapy - Direct oral anticoagulants (e.g., apixaban, rivaroxaban) - Thrombolytic agents (e.g., alteplase) - High‑dose antiplatelet agents in high‑bleeding‑risk patients

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs) - Selective serotonin reuptake inhibitors (SSRIs) or SNRIs - ACE inhibitors in patients with renal impairment - Diuretics that may alter renal clearance - Chemotherapy agents causing thrombocytopenia